The fusion protein MG7-scFv/SEB has shown anti-tumor activity on gastric cancer in vitro and in vivo. Tumor
necrosis factor-alpha (TNF-α) is a cytokine exerting anti-tumor effectiveness in various models and modes of applications.
In this study, we explored the combination effects of MG7-scFv/SEB and TNF-α in experimental gastric cancer.
Both MG7-scFv/SEB and TNF-α could effectively result in a significant inhibition of tumor growth in our experimental
models when administered alone. What’s more, MG7-scFv/SEB synergized with TNF-α in further reducing the growth of
gastric tumors in gastric-tumor-bearing rats as compared to mono therapy. Additionally, the survival rate of gastric-tumorbearing
rats administrated with combined therapy was significantly higher than that of rats treated with MG7-scFv/SEB or
TNF-α. These results indicate that combined therapy with MG7-scFv/SEB and TNF-α is a promising strategy for human
Keywords: Superantigens, MG7-scFv/SEB, tumor necrosis factor, combination, gastric cancer, fusion protein, cytokine, gastric tumor, combined therapy, cancer therapy
Rights & PermissionsPrintExport